Related references
Note: Only part of the references are listed.Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
Shuguang Tan et al.
PROTEIN & CELL (2018)
Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens
Mengjia Song et al.
CHINESE JOURNAL OF CANCER RESEARCH (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
David D. Stenehjem et al.
ONCOTARGETS AND THERAPY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Cemiplimab: First Global Approval
Anthony Markham et al.
DRUGS (2018)
Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers
Ying L. Liu et al.
CURRENT ONCOLOGY REPORTS (2018)
Comparison of the Toxicity Profile of PD-1 Versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Analysis of the Literature
Rathi N. Pillai et al.
CANCER (2018)
Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy
Kefang Liu et al.
CELL RESEARCH (2017)
Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab
Zhenkun Na et al.
CELL RESEARCH (2017)
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Mizuki Nishino et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab
Udupi A. Ramagopal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
Krzysztof M. Zak et al.
STRUCTURE (2017)
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
Shuguang Tan et al.
NATURE COMMUNICATIONS (2017)
Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab
Fei Zhang et al.
ONCOTARGET (2017)
Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies
Mengnan He et al.
ONCOTARGET (2017)
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Hyun Tae Lee et al.
SCIENTIFIC REPORTS (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
Cancer immunotherapies targeting the PD-1 signaling pathway
Yoshiko Iwai et al.
JOURNAL OF BIOMEDICAL SCIENCE (2017)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
Matteo S. Carlino et al.
CLINICAL CANCER RESEARCH (2016)
Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant
Roberta Pascolutti et al.
STRUCTURE (2016)
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Ju Yeon Lee et al.
NATURE COMMUNICATIONS (2016)
High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1
Shoichiro Horita et al.
SCIENTIFIC REPORTS (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
PD-1/PD-L1 inhibitors
Joel Sunshine et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab
Giovanna Scapin et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
Roy L. Maute et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
Krzysztof M. Zak et al.
STRUCTURE (2015)
Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab
Giovanna Scapin et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2015)
Nivolumab for the treatment of cancer
Anasuya Gunturi et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
Yanping Xiao et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
CANCER Antitumour immunity gets a boost
Jedd D. Wolchok et al.
NATURE (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies
Andrew J. S. Furness et al.
TRENDS IN IMMUNOLOGY (2014)
CD4 T Cells Require ICOS-Mediated PI3K Signaling to Increase T-Bet Expression in the Setting of Anti-CTLA-4 Therapy
Hong Chen et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Structure and Interactions of the Human Programmed Cell Death 1 Receptor
Xiaoxiao Cheng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Migration of Th1 Lymphocytes Is Regulated by CD152 (CTLA-4)-Mediated Signaling via PI3 Kinase-Dependent Akt Activation
Karin Knieke et al.
PLOS ONE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Rigid-body Ligand Recognition Drives Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Receptor Triggering
Chao Yu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A dimeric structure of PD-L1: functional units or evolutionary relics?
Yong Chen et al.
PROTEIN & CELL (2010)
Epitope landscape in breast and colorectal cancer
Neil H. Segal et al.
CANCER RESEARCH (2008)
CTLA-4 Activation of Phosphatidylinositol 3-Kinase (PI 3-K) and Protein Kinase B (PKB/AKT) Sustains T-Cell Anergy without Cell Death
Helga Schneider et al.
PLOS ONE (2008)
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
David Yin-Wei Lin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2
Eszter Lazar-Molnar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Inhibitory B7-family molecules in the tumour microenvironment
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2008)
PD-1 and PD-1 ligands: from discovery to clinical application
Taku Okazaki et al.
INTERNATIONAL IMMUNOLOGY (2007)
The consensus coding sequences of human breast and colorectal cancers
Tobias Sjoeblom et al.
SCIENCE (2006)
The PD-1-PD-L pathway in immunological tolerance
T Okazaki et al.
TRENDS IN IMMUNOLOGY (2006)
Crystal structure of a soluble CD28-Fab complex
EJ Evans et al.
NATURE IMMUNOLOGY (2005)
Structural and functional analysis of the costimulatory receptor programmed death-1
XW Zhang et al.
IMMUNITY (2004)
Crystal structure of the receptor-binding domain of human B7-2: Insights into organization and signaling
XW Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
New regulatory co-receptors: inducible co-stimulator and PD-1
T Okazaki et al.
CURRENT OPINION IN IMMUNOLOGY (2002)
CTLA-4: new insights into its biological function and use in tumor immunotherapy
JG Egen et al.
NATURE IMMUNOLOGY (2002)
PD-1: an inhibitory immunoreceptor involved in peripheral tolerance
H Nishimura et al.
TRENDS IN IMMUNOLOGY (2001)
Structural basis for co-stimulation by the human CTLA-4/B7-2 complex
JCD Schwartz et al.
NATURE (2001)
Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses
CC Stamper et al.
NATURE (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Structure of murine CTLA-4 and its role in modulating T cell responsiveness
DA Ostrov et al.
SCIENCE (2000)
Share Paper
